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Abstract: Deficiency in 25-hydroxyvitamin D (25[OH]D), the main
circulating form of vitamin D in blood, could be involved in the
pathogenesis of acute coronary syndromes (ACS). To date, however,
the possible prognostic relevance of 25 (OH)D deficiency in ACS
patients remains poorly defined. The purpose of this prospective study
was to assess the association between 25 (OH)D levels, at hospital
admission, with in-hospital and 1-year morbidity and mortality in an
unselected cohort of ACS patients.
We measured 25 (OH)D in 814 ACS patients at hospital presen-
tation. Vitamin D serum levels >30 ng/mL were considered as normal;
levels between 29 and 21 ng/mL were classified as insufficiency, and
levels< 20 ng/mL as deficiency. In-hospital and 1-year outcomes were
evaluated according to 25 (OH)D level quartiles, using the lowest
quartile as a reference.
Ninety-three (11%) patients had normal 25 (OH)D levels, whereas
155 (19%) and 566 (70%) had vitamin D insufficiency and deficiency,
respectively. The median 25 (OH)D level was similar in ST-elevation
myocardial infarction (STEMI) and non-ST-elevation myocardial
infarction (NSTEMI) patients (14.1 [IQR 9.0–21.9] ng/mL and
14.05 [IQR 9.1–22.05] ng/mL, respectively; P¼ .88).The lowest quar-
tile of 25 (OH)Dwas associated with a higher risk for several in-hospital
complications, including mortality. At a median follow-up of 366 (IQR
364–379) days, the lowest quartile of 25 (OH)D, after adjustment for the
main confounding factors, remained significantly associated to 1-year
mortality (P< .01). Similar results were obtained when STEMI and
NSTEMI patients were considered separately.
In ACS patients, severe vitamin D deficiency is independently
associated with poor in-hospital and 1-year outcomes. Whether low
vitamin D levels represent a risk marker or a risk factor in ACS remains
to be elucidated.i, PhD, Marina Ca
iancarlo Marenzi, MD
Abbreviations: 25 (OH)D = 25-hydroxyvitamin D, ACS = acute
coronary syndromes, ADHF = acute decompensated heart failure,
BMI = body mass index, IQR = interquartile ranges, LVEF = left
ventricular ejection fraction, MACE = major adverse clinical
events, NSTEMI = non-ST-elevation myocardial infarction, PCI =
percutaneous coronary intervention, sCr = serum creatinine,
STEMI = ST-elevation myocardial infarction.
INTRODUCTION
B eyond its fundamental role in bone metabolism and calciumhomeostasis, vitamin D may influence several other
medical conditions, including cardiovascular disease. Indeed,
vitamin D receptors have been found in the myocardium as well
as in vascular cells, and hypovitaminosis D, a common finding
in many industrialized countries, has been independently
associated with increased risk of developing acute myocardial
infarction and heart failure.1,2 Moreover, vitamin D deficiency
has been linked to conditions, such as hypertension, diabetes
mellitus, metabolic syndrome, cardiac hypertrophy, and chronic
kidney disease, that predispose to cardiovascular disease.3–7
More importantly, in heart failure patients, vitamin D supple-
mentation has been shown to be associated with improved
survival.8 Several studies have also demonstrated a survival
benefit in end-stage renal disease patients treated with vitamin
D, primarily related to a reduction in cardiovascular death.9
Thus, vitamin D seems to play an important role in cardiac
function and in the development and progression of coronary
artery disease.
Deficiency of vitamin D, or of 25-hydroxyvitamin D
(25[OH]D), its main circulating form in the blood, has been
recently reported to be common in patients with acute coronary
syndromes (ACS),10 and preliminary studies indicate a possible
association with prognosis. Very few studies, however, have
investigated the association between vitamin D levels and
clinical outcomes in ACS patients thus far; moreover, they
were either underpowered to evaluate in-hospital outcomes, or
mainly focused on long-term results.11–14 Therefore, convin-
cing data demonstrating the possible impact of vitamin D
insufficiency, or deficiency, on morbidity and mortality of
ACS patients are still lacking. Notably, vitamin D has been
demonstrated to suppress the renin-angiotensin system and to
affect endothelial function, inflammatory processes, platelet
function, insulin resistance, and blood pressure.3,15–18 All these
effects are relevant during ACS, and related to patients’ clinicallevels of vitamin D have been associated
ction and cardiac remodeling after ACS,
ortality and sudden cardiac death.11,19,20
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Thus, both the short- and long-term outcomes of ACS patients
could be significantly affected by vitamin D status.
The purpose of this prospective study was to determine the
clinical implications of 25 (OH)D levels in an unselected cohort
of ACS patients at hospital admission, and their possible
association with in-hospital and 1-year morbidity and mortality.
MATERIAL AND METHODS
Study Population
This was a prospective, observational study. All consecu-
tive ACS patients, including both ST-elevation myocardial
infarction (STEMI) and non-ST elevation myocardial infarction
(NSTEMI) patients, admitted to the Intensive Cardiac Care Unit
of Centro Cardiologico Monzino, between June 1st, 2010 and
October 31st, 2012 were recruited. Patients on chronic perito-
neal or hemodialysis treatment were excluded. Patients experi-
encing acute myocardial infarction after elective percutaneous
coronary intervention (PCI), those with known malignancy
and those with short life expectancy, were also excluded.
The study was approved by the Institutional Review Board
of our centre (Centro Cardiologico Monzino, Milan, Italy), and
written informed consent was obtained from all participants. No
extramural funding was used to support this work.
Study Protocol
In all patients a venous blood sample (3.5mL) was drawn
at hospital admission and biological measurement of 25 (OH)D
was available for all enrolled patients. Architect 25-OH vitamin
D assay (Abbott Diagnostics, Wiesbaden, Germany), with a
limit of detection of 7 ng/mL, was used for serum 25 (OH)D
measurement; values below this limit were considered 6.9ng/mL.
According to published data, and to the US Endocrine Society
guideline recommendations,21 we used the following cut-off
values for classifying vitamin D status: >30 ng/mL were con-
sidered normal vitamin D levels; between 29 and 21 ng/mL
were classified as vitamin D insufficiency, and< 20 ng/mL as
vitamin D deficiency. As most patients were expected to present
low vitamin D levels,10 the sample was also stratified into
25 (OH)D quartiles, in order to maximize statistical power.
All patients received standard medical treatment and cor-
onary revascularization at the discretion of the attending phys-
ician, on the basis of the current standards of care recommended
by published guidelines.
Demographical, clinical, biochemical, echocardiographic,
and angiographic data were obtained. The estimated glomerular
filtration rate was calculated according to the Modification of
Diet in Renal Disease (MDRD) formula.22 The left ventricular
ejection fraction (LVEF; echocardiogram) was measured in all
patients within 24 hours from hospital admission.
In all patients undergoing coronary angiography, the extent
of angiographic coronary artery disease was quantified by the
SYNTAX score.23 A team of 2 interventional cardiologists,
blinded to the patients’ clinical characteristics and vitamin D
result, calculated the SYNTAX score.
After hospital discharge, all patients were followed up for at
least 1 year. Patient follow-up was mainly obtained through
regularly scheduled outpatient visits or, in a minority of cases,
by telephone contacts performed by dedicated medical personnel.
De Metrio et al.Study End Points
The primary end point of the study was 1-year mortality.
In-hospital mortality and in-hospital major adverse clinical
2 | www.md-journal.comevents (MACEs) (death, major bleeding [requiring blood trans-
fusion], acute pulmonary edema [with or without the need
for mechanical ventilation], cardiogenic shock, clinically sig-
nificant tachyarrhythmias [ventricular fibrillation, sustained
ventricular tachycardia, and atrial fibrillation] and bradyar-
rhythmias requiring pacemaker implantation, and acute kidney
injury [defined according to the Acute Kidney Injury Network
classification]24) were evaluated as secondary end points. At
1-year follow-up, the following events were also considered: 1)
re-hospitalization for ACS; 2) re-hospitalization for acute
decompensated heart failure (ADHF); 3) other relevant clinical
events [stroke, major bleeding, and life-threatening tachyar-
rhythmias]; 4) and the composite of death, re-hospitalization for
ACS and ADHF, and other relevant clinical events (combined
end point).
Statistical Analysis
A sample size of 800 patients was calculated under the
following assumptions: 6% overall 1-year mortality, with an
expected 8.5% and 2% mortality in patients with the lowest and
the highest 25 (OH)D plasma level quartile, respectively. This
sample size allowed >80% statistical power in assessing sig-
nificantly different (a error of 0.05) 1-year mortality between
the 2 groups.
Continuous variables are presented as meanSD. Vari-
ables with a skewed distribution are presented as median and
interquartile ranges (IQR), and were transformed in logarithm
before analysis. Categorical data are presented as n (%). Trends
across 25 (OH)D quartiles were assessed by ANCOVA for
continuous variables and by Mantel-Haenszel chi-square. The
association between 25 (OH)D and in-hospital and 1-year
clinical outcomes was assessed by logistic regression and by
Cox regression analysis, respectively. Analyses were adjusted
for potential confounders selected among the most important
recognized clinical predictors of mortality (ie, age, LVEF,
diabetes mellitus, and baseline serum creatinine concentration
[sCr]), and among correlates of vitamin D levels observed in our
cohort (body mass index [BMI], high-sensitivity-C-reactive
protein, total cholesterol, and triglycerides); results are pre-
sented as odds ratios or hazard ratio with 95% confidence
intervals. Patients were grouped into quartiles according to
25 (OH)D levels, using the lowest quartile as a reference.
Kaplan-Meier analysis was employed to generate time-to-
event curves for the 1-year end points (mortality and combined
end point), stratified according to 25 (OH)D< 9 ng/mL. Log
rank test was used to compare strata.
All tests were 2-tailed, and a P value of less than .05 was
required for statistical significance. All calculations were com-
puted with the aid of the SAS software package (Version 9.2
SAS Institute Inc., Cary, NC).
RESULTS
Patient Characteristics
A total of 814 consecutive ACS patients (mean age
67 12 years, 584 men; 341 STEMI and 473 NSTEMI patients)
were included in this study. Out of them, 93 (11%) patients
had normal 25 (OH)D levels at hospital admission, whereas
155 (19%) and 566 (70%) had vitamin D insufficiency and
deficiency, respectively. No difference in this proportion was
Medicine  Volume 94, Number 19, May 2015observed between STEMI and NSTEMI patients (Figure 1).
The median 25 (OH)D level in the whole population was 14.05
(IQR 9.0–22.0) ng/mL; it was similar in STEMI and NSTEMI
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.
FIGURE 1. Vitamin D levels in ST-elevation myocardial infarction
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22.05] ng/mL, respectively; P¼ .88).
Table 1 reports patient characteristics according to 25
(OH)D quartiles. Patients in the low 25 (OH)D quartiles were
older, more frequently diabetics, with a lower LVEF, and with
higher high-sensitivity C-reactive protein levels. Notably, the
percentage of STEMI patients was similar in the 4 groups, as
well as the extent of coronary disease, as evaluated by the
SYNTAX score.
Association Between Vitamin D and in-Hospital
Outcomes
The overall in-hospital mortality in all study patients was
2.6% (n¼ 21), and it was higher in STEMI than in NSTEMI
patients (4.7% vs. 1.1%; P< .01). The lowest quartile of 25
(OH)D was associated with a higher risk for several in-hospital
MACEs, including mortality (Table 2). After adjustment for
major confounders, vitamin D remained a significant indepen-
dent predictor of major bleeding and mechanical ventilation
only, with a borderline statistical significance with mortality.
Association Between Vitamin D and 1-Year
Outcomes
Outcome data at 1-year follow-up were obtained for 796
(98%) patients, with a median follow-up period of 366 (IQR
364–379) days. After hospital discharge, 28 additional patients
died, resulting in a cumulative mortality rate of 6% (n¼ 49)
(6.6% in STEMI and 5.8% in NSTEMI patients; P¼ .63). Forty-
four (5.5%) patients were re-admitted for a new ACS, and 25
(3.1%) for ADHF. Finally, there were a total of 7 (0.9%) major
adverse events. After adjustment for major confounders, vita-
min D remained significantly associated to 1-year mortality and
re-hospitalization for ADHF in our population (Table 3).
The Kaplan–Meier survival curves provided confirmation
that the lowest 25 (OH)D quartile was associated with 1-year
mortality (Figure 2, Panel A) (P< .01 by log rank test vs. the
other 3 quartiles pooled together) and to combined end point of
death, re-hospitalizations for ACS and ADHF, and other
(STEMI) and non-ST elevation myocardial infarction (NSTEMI)
patients. 25 (OH)D¼25-hydroxyvitamin D. P value was obtained
by chi-square test.relevant clinical events (Figure 2, Panel B; P< .01). Similar
results were obtained when STEMI and NSTEMI patients were
considered separately (Figure 3).
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The present prospective study, aimed at investigating the
role of vitamin D in a consecutive, nonselected cohort of ACS
patients, demonstrated an independent association between
its severe deficiency (the lowest quartile) and in-hospital and
1-year clinical outcomes.
Multiple lines of evidence suggest a link between vitamin
D and cardiovascular disease. Epidemiological studies reported
that the rates of coronary artery disease, diabetes, hypertension,
as well as of vitamin D deficiency, increase in proportion to
increasing distance from the equator.25 Cardiac death has also
been reported to be at its highest during periods of decreased
sunlight exposure (ie, winter months).26 Moreover, observa-
tional studies, small clinical trials, and meta-analyses indicate
that vitamin D therapy may reduce cardiovascular events and
mortality.8,27,28 Although these data from apparent healthy
subjects support a role of vitamin D deficiency as a new
potential cardiovascular risk factor, there is still paucity of
information regarding the implications of vitamin D deficiency
in ACS and its possible association, or causal relationship, with
morbidity and mortality. Clinical interest derives from the fact
that vitamin D deficiency can be readily determined by blood
testing and treated by supplementation. In particular, a single
oral ultra-high dose of vitamin D has been shown to restore
normal 25 (OH)D levels within 2 days in critically ill patients,
without causing adverse effects, thus providing the basis of an
easy-to-administer dosing regimen for prospective intervention
trials in acute cardiovascular settings.29
In the last few years, growing interest has emerged on the
possible implications of low vitamin D levels in ACS. Lee
et al10 assessed 25 (OH)D levels in 239 patients enrolled in a
multicenter prospective registry, and found a high (96%) preva-
lence of vitamin D deficiency in patients with acute myocardial
infarction. After this first report, further studies have confirmed
this observation and investigated its possible clinical and prog-
nostic relevance. In the Khalili et al11 study, a significant
inverse relationship between serum levels of matrix metallo-
proteinase-9 (an early marker of cardiac remodeling), evaluated
72 hours after hospital admission, and vitamin D was found in
139 STEMI patients, suggesting a possible role of vitamin D in
influencing cardiac remodeling. The authors also reported a
possible correlation between low levels of vitamin D and
increased in-hospital mortality. Given the small sample size
of their population, however, the study was significantly under-
powered to detect any difference in mortality between STEMI
patients with normal and low vitamin D levels.12 In another
study, Correia et al13 reported a possible independent associ-
ation between vitamin D deficiency and in-hospital cardio-
vascular mortality. Again, in this study the sample size was
relatively small (n¼ 206), STEMI patients were underrepre-
sented (7% of all patients), and deaths for complications
occurring after bypass surgery were also considered. Therefore,
no definite conclusion can be drawn at this time on in-hospital
clinical relevance of vitamin D deficiency. Thus far, the largest
study evaluating vitamin D and prognosis in ACS patients was
that by Ng et al14 They found an association between the lowest
vitamin D quartile (<7.3 ng/mL) and long-term major adverse
cardiovascular outcomes in 1259 patients. Notably, the associ-
ation was predominantly with nonfatal adverse outcomes, such
as re-hospitalization for ADHF or for another ACS, rather
than mortality.
Vitamin D in Acute Coronary SyndromesOur study supports the close association between low
vitamin D levels at hospital presentation and worse prognosis
in ACS patients. Indeed, patients in the 25 (OH)D lowest
www.md-journal.com | 3
TABLE 1. Baseline characteristics of study patients according to 25(OH)D quartiles
25-OHD quartiles
All 1 2 3 4
<9 ng/mL 9–13.9 ng/mL 14–22ng/mL >22 ng/mL
(n¼ 814) (n¼ 204) (n¼ 203) (n¼ 206) (n¼ 201) P value
Age (years) 67 12 69 14 67 12 65 12 66 12 0.0035
Male sex, n (%) 584 (72%) 134 (66%) 150 (78%) 161 (78%) 139 (69%) 0.29
Body weight (kg) 76 15 75 16 77 15 78 14 74 14 0.57
Height (cm) 168 9 167 9 169 9 170 9 168 9 0.22
BMI 26.70 4.35 27.05 5.40 26.61 3.90 26.94 3.87 26.18 3.92 0.09
STEMI, n (%) 341 (42%) 87 (43%) 83 (41%) 88 (43%) 83 (41%) 0.88
Diabetes mellitus, n (%) 187 (23%) 63 (31%) 49 (24%) 46 (22%) 29 (14%) <0.001
Hypertension, n (%) 514 (63%) 134 (66%) 127 (63%) 123 (60%) 130 (65%) 0.69
Smokers, n (%) 446 (55%) 101 (49%) 122 (60%) 125 (61%) 98 (49%) 0.77
Hyperlipidemia, n (%) 420 (52%) 104 (51%) 113 (56%) 100 (48%) 103 (51%) 0.65
Previous MI, n, (%) 221 (27%) 46 (22%) 56 (28%) 64 (31%) 55 (27%) 0.20
Previous bypass surgery, n (%) 101 (12%) 21 (10%) 37 (18%) 24 (12%) 19 (9%) 0.39
Previous PCI, n (%) 210 (26%) 45 (22%) 58 (29%) 54 (26%) 53 (26%) 0.44
LVEF (%) 52 12 51 13 51 12 53 12 53 13 0.05
SAP (mmHg) 139 15 136 12 137 14 142 16 141 16 0.72
DAP (mmHg) 83 8 82 6 84 7 84 9 83 9 0.84
Time-to-ED (hours) 3.7 (2–10) 3.0 (2–10) 3.0 (2–10) 3.2 (2–8) 4.0 (2–10) 0.50
Hospital admission laboratory values
Blood glucose (mg/dL) 130 (109–171) 134 (109–190) 133 (111–162) 128 (109–171) 126 (107–152) 0.002
Hemoglobin A1c (mmol/mol) 40 (36–46) 41 (28–49) 40 (36–46) 40 (36–46) 38 (35–43) <0.001
Serum creatinine (mg/dL) 0.91 (0.77–1.12)0.88 (0.75–1.22) 0.91 (0.76–1.1) 0.93 (0.8–1.09) 0.93 (0.79–1.1) 0.65
eGFR (mL/min/1.73m2) 83 29 81 34 84 28 84 26 81 27 0.90
Hemoglobin (g/dL) 13.5 1.7 13.3 1.9 13.4 1.8 13.6 1.6 13.6 1.6 0.07
Troponin I (ng/mL) 4.6 17 4.2 14 4.1 11 4.3 15 5.9 24 0.31
Peak troponin I (ng/mL) 44 131 53 165 50 166 36 63 37 99 0.14
Total cholesterol (mg/dL) 181 47 186 50 180 49 181 46 174 42 0.024
HDL (mg/dL) 40 12 40 12 40 12 39 11 42 12 0.21
LDL (mg/dL) 116 42 119 45 114 42 118 42 111 39 0.15
Triglycerides (mg/dL) 105 (78–150) 113 (78–162) 104 (76–162) 105 (77–147) 94 (72–135) <0.001
hs-CRP (mg/dL) 3.3 (1.2–11) 5.2 (1.9–16.6) 3.3 (1.1–8.8) 2.7 (1.0–7.5) 2.7 (1.2–8.9) 0.01
25 (OH)D (ng/mL) 14.05 (9–22) 6.9 (7–8) 11.5 (10–13) 17.8 (16–20) 29.1 (24–37) –
Medication before ACS
Statins 280 (34%) 59 (29%) 73 (36%) 74 (36%) 74 (37%) 0.12
ACE-inhibitors/ARB 350 (43%) 87 (42%) 93 (46%) 77 (37%) 93 (46%) 0.92
Beta-blockers 307 (38%) 69 (34%) 79 (39%) 76 (37%) 83 (41%) 0.20
Aspirin 589 (72%) 150 (74%) 146 (72%) 153 (74%) 140 (70%) 0.84
Warfarin 36 (4%) 11 (5%) 9 (4%) 6 (3%) 10 (5%) 0.66
Vitamin D supplementation 9 (1%) 1 (0.5%) 1 (0.5%) 0 (0%) 7 (3.5%) 0.01
In-hospital procedures
Coronary angiography 751 (92%) 178 (87%) 188 (93%) 194 (94%) 191 (95%) 0.003
PCI 625 (77%) 149 (73%) 146 (72%) 170 (83%) 160 (80%) 0.03
Bypass surgery 41 (5%) 8 (4%) 12 (6%) 7 (3%) 14 (7%) 0.31
SYNTAX score 15 (6–25.5) 15 (6–29) 11 (6–23) 13.5 (5–24) 16.5 (7–28) 0.42
25 (OH)D¼ 25-hydroxyvitamin D, ACE¼ angiotensin-converting enzyme, ACS¼ acute coronary syndromes, ARB¼ angiotensin II receptor
blocker, BMI¼ body mass index, DAP¼ diastolic arterial pressure, eGFR¼ estimated glomerular filtration rate, HDL¼ high-density lipoprotein, hs-
CRP¼ high-sensitivity C-reactive protein, LDL¼ low-density lipoprotein, LVEF¼ left ventricular ejection fraction, MI¼myocardial infarction,
PCI¼ percutaneous coronary intervention, SAP¼ systolic arterial pressure, STEMI¼ST-elevation myocardial infarction, Time-to-ED¼Time from
onset of pain to arrival in emergency department.
P for trend.
De Metrio et al. Medicine  Volume 94, Number 19, May 2015
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TABLE 3. Association between the lowest 25 (OH)D quartile and 1-year adverse events. Data are also presented after adjustment
for major potential confounding (age, body mass index, diabetes mellitus, left ventricular ejection fraction, serum creatinine,
high-sensitivity-C-reactive protein, total cholesterol, and triglycerides)
Unadjusted Adjusted
1-year adverse event n (%) HR (95% CI) P value HR (95% CI) P value
Mortality 49 (6.2%) 3.06 (1.71–5.46) 0.0002 2.51 (1.35–4.65) 0.003
Re-hospitalization for ACS 44 (5.5%) 0.92 (0.43–1.88) 0.78 0.87 (0.41–1.87) 0.72
Re-hospitalization for ADHF 25 (3.1%) 2.74 (1.24–6.05) 0.012 2.72 (1.14–6.45) 0.02
Other relevant clinical events 7 (0.9%) 2.71 (0.61–12.18) 0.19 3.11 (0.55–17.69) 0.20
Combined end point

125 (15.4%) 2.02 (1.40–2.92) 0.0002 1.85 (1.25–2.75) 0.002
ACS¼ acute coronary syndromes, ADHF¼ acute decompensated heart failure, HR¼ hazard ratio.
Death, rehospitalization for ACS and ADHF, and other relevant clinical events.
TABLE 2. Association between the lowest 25 (OH)D quartile and in-hospital events. Data are also presented after adjustment
for major potential confounding (age, body mass index, diabetes mellitus, left ventricular ejection fraction, serum creatinine,
high-sensitivity-C-reactive protein, total cholesterol, and triglycerides)
In-hospital event Unadjusted Adjusted
n (%) OR (95% CI) P value OR (95% CI) P value
Mortality 21 (2.6%) 3.11 (1.13–8.57) 0.02 2.74 (0.95–7.83) 0.06
Cardiogenic shock 39 (4.8%) 1.53 (0.77–3.03) 0.22 1.42 (0.64–3.14) 0.38
Acute pulmonary edema 70 (8.6%) 2.15 (1.30–3.57) 0.003 1.61 (0.85–3.04) 0.14
Mechanical ventilation 36 (4.4%) 2.51 (1.27–4.94) 0.007 2.58 (1.16–5.71) 0.02
Major bleeding 39 (4.8%) 3.38 (1.77–6.47) <0.001 2.85 (1.36–5.97) 0.005
Acute kidney injury 101 (12.4%) 1.62 (1.04–2.53) 0.03 1.36 (0.80–2.32) 0.26
Acute kidney injury requiring RRT 21 (2.6%) 1.87 (0.76–4.59) 0.017 1.24 (0.43–3.51) 0.69
VT/VF 46 (5.6%) 1.33 (0.69–2.54) 0.38 1.69 (0.82–3.48) 0.15
AV-block requiring PM 21 (2.6%) 0.93 (0.33–2.57) 0.83 0.63 (0.19–2.01) 0.43
Atrial fibrillation 82 (10.1%) 1.90 (1.23–2.93) 0.003 1.47 (0.89–2.39) 0.12
All complications 231 (28.4%) 1.74 (1.24–2.44) 0.001 1.75 (1.17–2.63) 0.006
AV¼ atrio-ventricular, PM¼ pacemaker, RRT¼ renal replacement therapy, VF¼ ventricular fibrillation, VT¼ ventricular tachycardia.
FIGURE 2. Kaplan-Meier curve analysis stratified according to 25 (OH)D levels (the lowest quartile [red line] vs. the other 3 quartiles
pooled together [blue line]) for 1-year mortality (Panel A), and for the combined end point (Panel B), in the whole study population.
P value by Log rank test.
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FIGURE 3. Kaplan-Meier curve analysis stratified according to 25 (OH)D levels (the lowest quartile [red line] vs. the other 3 quartiles
, an
STe
De Metrio et al. Medicine  Volume 94, Number 19, May 2015quartile had a 2-fold higher mortality risk, even after adjustment
for important independent variables associated with mortality in
ACS.30–32 Notably, patients with STEMI and NSTEMI had a
similar vitamin D status and portrayed a comparable mortality
risk. Thus, our results strengthen the evidence of a close
association between low vitamin D levels and poor outcome,
and they pave the way for studies based on pharmacologic
supplementation of vitamin D in selected high-risk ACS
patients, namely those with severe vitamin D deficiency, in
order to improve their prognosis.
The possible causal relationship underlying the association
between vitamin D status and outcomes in ACS remains to be
elucidated. Mechanisms by which vitamin D deficiency may
confer an increased cardiovascular risk, directly or indirectly
leading to hyperparathyroidism, include renin-angiotensin-sys-
tem activation and disorders of insulin synthesis, secretion, and
sensitivity, that influence glycemic control and may favor the
onset of diabetes.3,6,15,33 Of note, low blood 25OH-D concen-
trations have been associated with an increased risk of both
macrovascular and microvascular disease events in type 2
diabetes.34 However, in our study, the prognostic implications
of vitamin D were confirmed also after adjustment for diabetes.
Other potential consequences of vitamin D deficiency
involve exacerbation of atherogenesis, inflammation, accelera-
tion of arterial calcification, cardiac remodeling and systolic
dysfunction, higher risk of restenosis following PCI, and influ-
ence on lipid levels.9,17–20,35–37 Additionally, vitamin D
deficiency has been associated with endothelial dysfunction,38
which is, in turn, linked to an increased risk of cardiovascular
pooled together [blue line]) for 1-year mortality (Panels A and C)
ST-elevationmyocardial infarction (STEMI) (upper panels) and non-
Log rank test.events.39 In particular, the endothelium mediates vascular tone
control, platelet aggregation, endothelium permeability, and
neoangiogenesis40–42; thus, its dysfunction may exacerbate
6 | www.md-journal.comcoronary thrombosis and vasoconstriction occurring during
ACS. Finally, in our study, patients with lower vitamin D
levels had higher high-sensitivity C-reactive protein values,
suggesting a possible link between low vitamin D levels and
inflammation. However, controversial data exist on this
possible relationship, as recently reported by Eren et al.,43
who found no association between calcidiol levels and inflam-
matory markers in ACS. Overall, all these features, associated
with older age, higher cholesterol and triglycerides levels, and
less aggressive coronary reperfusion strategy, may contribute to
explain the worse outcome of ACS patients with vitamin D
deficiency in our study. Whether vitamin D serves as a risk
factor or as a risk marker in ACS, however, cannot be deduced
from our study, and future investigation is warranted to clarify
this issue. Indeed, frail patients with high cardiovascular risk
burden, because of their health status may spend more time
indoors and have less sun exposure, leading to vitamin D
deficiency. Although a clear evidence that patients with cardi-
ovascular disease have lower levels of 25 (OH)D, a similar
association exists for a large number of other medical con-
ditions, like cancer, multiple sclerosis, and psychiatric diseases,
supporting the concept that vitamin D is simply a general
marker of health.44
An important novelty of our study was the link between
vitamin D levels and in-hospital outcomes. Only a trend toward
a higher in-hospital mortality rate of patients having the lowest
25 (OH)D quartile was observed, possibly due to the relatively
low in-hospital mortality rate of our population. An interesting
finding was the association between lowest vitamin D levels and
d for the combined end point (Panels B and D), in patients with
levationmyocardial infarction (NSTEMI) (lower panels).P value bysome major in-hospital clinical complications. In particular,
patients in the lowest 25 (OH)D quartile had a significantly
higher risk of bleeding requiring transfusion, despite similar
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.
hemoglobin levels at hospital admission. This represents a
critical issue in ACS, where potent antithrombotic therapy is
the mainstay of treatment, and where major bleeding, as well as
the need for transfusion, has a relevant negative impact on
prognosis. The reason (s) for this association is unclear. Possible
explanations might involve anticoagulant effects by up-regulat-
ing thrombomodulin and down-regulating tissue factor, and
interaction with platelet function.45–47
Another interesting association found in our study was
between the lowest 25 (OH)D quartile and the risk of acute
respiratory insufficiency. This finding could be explained by
left ventricular dysfunction, muscle weakness and increased
infectious risk associated with low vitamin D levels and/or with
transfusion-related acute lung injury.6,44,48 The higher inci-
dence of all these life-threatening complications might contrib-
ute, at least in part, to the higher in-hospital mortality risk
observed in ACS patients with vitamin D deficiency.
Obviously, these findings should be confirmed in larger studies,
and future investigation is also needed to elucidate whether
supplementation of vitamin D, aimed at rapidly normalizing 25
(OH)D levels in ACS patients, may reduce the incidence of
these complications and, finally, improve patients’ in-hospital
outcome.
Some limitations warrant mention. First, we included a
population admitted to a single center. Second, the study
population was possibly underpowered to detect a significant
difference in in-hospital mortality. Third, our data are only
hypothesis generating, because they do not provide evidence to
support a causal relationship, and they require confirmation in
suitably designed clinical trials. Finally, many factors that affect
vitamin D status (eg, latitude, season, sunlight exposure, skin
color, vitamin D intake, serum albumin, etc.) were not taken
into account in our study, and may have influenced, at least in
part, our results.
In conclusion, this study demonstrated the presence of an
association between vitamin D deficiency and poor in-hospital
and 1-year outcomes in patients with ACS. The correction of
vitamin D deficiency and maintenance of an optimal status may
be a promising approach for acute treatment and secondary
prevention of ACS that requires confirmation in interventional
trials with vitamin D supplementation.
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